Immunovant (IMVT) total debt

Total debt · fiscal 2026
$72.00K

Immunovant (IMVT) carried total debt of $72.00K at the end of fiscal 2026 (March 31, 2026). That is 26.5% lower than the $98.00K of fiscal 2025. Figures as of 17 Nov 2026, 23:50 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total debt, fiscal 2026
$72.00K
Change on fiscal 2025
−26.5%
Highest on record
$1.22Mfiscal 2023
Lowest on record
$72.00Kfiscal 2026
Fiscal years on record
42023–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Immunovant total debt, in more detail

Across the 4 fiscal years on record (2023–2026), the highest was $1.22M in fiscal 2023 and the lowest $72.00K in fiscal 2026.

Total debt was 0.0× shareholders' equity at the end of fiscal 2026.

History · 4 fiscal years

Total debt by fiscal year

Immunovant total debt, year by year

Immunovant (IMVT) total debt by fiscal year
Fiscal yearTotal debtChangeYear endedDebt ÷ equity
2026$72.00K 26.5% down0.0×
2025$98.00K 29.0% down0.0×
2024$138.00K 88.7% down0.0×
2023$1.22M—0.0×

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.

How to read it

Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.

Total debt at health care companies of similar size

Total debt of Immunovant and comparable companies
CompanyTotal debtFiscal year
Bausch + Lomb BLCO$5.08B2025
Amneal Pharmaceuticals AMRX$2.69B2025
Caris Life Sciences CAI$427.69M2025
Immunovant IMVT$72.00K2026
Axsome Therapeutics AXSM$218.11M2025
Chemed CHE$143.76M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on IMVT

Immunovant, figure by figure

Immunovant (IMVT) overview: price, valuation and scorecardAll health care companies by market value

Immunovant total debt: questions and answers

How much debt does Immunovant have?

Immunovant (IMVT) carried total debt of $72.00K at the end of fiscal 2026 (March 31, 2026). That is 26.5% lower than the $98.00K of fiscal 2025.

What are the highest and lowest total debt figures on record for Immunovant?

Across the 4 fiscal years on record (2023–2026), the highest was $1.22M in fiscal 2023 and the lowest $72.00K in fiscal 2026.

How does Immunovant's debt compare with its equity?

Total debt was 0.0× shareholders' equity at the end of fiscal 2026.

How is Immunovant's total debt calculated?

Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Immunovant (IMVT) total debt”, data as of 17 November 2026. https://funkfolio.com/stock/IMVT/total-debt

Underlying data: the company's filings with the SEC and Yahoo Finance.